| |APRIL 20268ALEMBIC PHARMA WINS USFDA NOD FOR GENERIC MENTAL HEALTH DRUGAlembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its generic mental health drug -- Paroxetine extended-release tablets, a medication commonly used to treat mental health conditions.The approval is for Paroxetine extended-release tablets USP, 12.5 mg. This drug is a generic equivalent of Paxil CR and is prescribed for conditions such as depression, anxiety disorders, panic disorder, and premenstrual dysphoric disorder.This development strengthens Alembic's position in the United States pharmaceutical market, which remains one of the most important and competitive globally. By adding this product to its portfolio, the company is expanding its presence in the mental health treatment segment, where demand continues to remain steady.With this approval, Alembic Pharmaceuticals now has a total of over 200 ANDA approvals from the USFDA, including both final and tentative clearances. The company has been consistently focusing on growing its generics business in regulated markets, especially in the US.Industry experts see this approval as another step forward for Indian pharmaceutical companies, which have been steadily increasing their footprint in the global generics market. Their ability to offer cost-effective medicines while meeting strict regulatory standards has helped them remain competitive.For Alembic, this approval is not just about adding another product. It reflects a broader strategy of targeting therapies that have long-term demand and stable market potential. Mental health treatments fall squarely into this category, making them a key area of focus.Overall, the USFDA approval is expected to support Alembic's growth in international markets and strengthen its product pipeline. As the company continues to pursue more approvals, it is clearly aiming to build a stronger and more diversified presence in the global pharmaceutical industry. POTOP STORIESNOVO NORDISK REDUCES OZEMPIC PRICE TO COMPETE WITH INDIAN GENERICSNovo Nordisk is set to cut the Ozempic price in India as Indian generics flood the market following the patent expiry.The Danish company aims to stay competitive against low-cost semaglutide injections launched by local pharma players. With generics priced significantly lower, Novo Nordisk's move ensures patients still have access to its branded Ozempic while the company protects its market share in India's growing diabetes and obesity treatment sector.The move marks a major shift for Novo Nordisk's Ozempic pricing strategy in one of the world's fastest-growing diabetes and obesity treatment markets. Indian pharmaceutical companies including Sun Pharma, Dr. Reddy's and Zydus have launched their own generic semaglutide injections within days of the patent lapse. Those generics are priced at a fraction of the branded drug, pushing Novo to cut its list price by roughly 30­50 percent to stay competitive.Ozempic, which currently sells for about Rs 8,800 to Rs 11,175 per month in India, may be reduced to around Rs 5,000-Rs 6,000 under the new pricing plan. Even after the discount, this price will still sit above many generic rivals. The company aims to protect its market share and doctor loyalty as customers and healthcare providers shift attention to more affordable semaglutide options.Generics now available are significantly cheaper, with some priced under Rs 5,000 per month and headline discount levels as steep as 70-90 percent compared with branded equivalents. This puts pressure on Novo Nordisk's traditional premium pricing model for Ozempic, which helped establish its foothold in diabetes and weight-loss therapy but now faces disruption across India's price-sensitive healthcare landscape. PO
< Page 7 | Page 9 >